Michael brings an extensive knowledge and expertise in molecular genetics, signal transduction, and cell engineering and is the inventor of the iLite™ reporter gene technology.
Michael is the author of more than 200 articles on cytokines, biotechnology, and immunogenicity. He is a member of numerous scientific boards, Chair of the International Cytokines Standards Committee, Chair of the Coral Gables Symposia, French representative ICIS International Council, member of the ICIS Meetings Committee, member of the European Adjuvant Advisory Committee, Editor-in-Chief of Detection and Quantification of Antibodies to Biopharmaceuticals, Associate Editor of the Journal of Interferon and Cytokine Research, Associate Editor of Cytokine, Associate Editor of the World Scientific Journal, and a member of the editorial boards of numerous journals.
In July 2014 Euro Diagnostica, a leader in diagnostic solutions for autoimmune diseases, entered into a merger agreement with Biomonitor, a leading company in theranostics and personalized medicine. Biomonitor’s patented cell-based assay platform iLite™, based on reporter gene technology, can both monitor functional drug activity and detect neutralizing antibodies. This provides a unique and extremely versatile tool for optimizing patient treatment.
For questions and further details, please contact:
Else Beth Trautner, CEO
Mobile: +46 70 274 85 71
Biomonitor A/S is a leader in theranostics that offers patient monitoring services and specialized CRO services at the GLP Clinical Reference Lab in Copenhagen. The company also provides customized assay development to pharma and biotech companies. The tests are based on the gene reporter technology for cell-based assays and kits called iLite™. This proprietary platform is unique in measuring potency as well as antibodies to biologicals in a simple and rapid test format.
Euro Diagnostica’s goal is to constantly develop solutions to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune and related diseases. Today Euro Diagnostica is based on four segments; a portfolio of ELISA and RIA kits, Wieslab lab services, OEM/custom manufacturing and drug monitoring.« Back